[1]
|
Talley, N.J., Abreu, M.T., Achkar, J.P., et al. (2011) An evidence-based systematic review on medical therapies for inflammatory bowel disease. American Journal of Gastroenterology, 106, S2-S25. doi:10.1038/ajg.2011.58
|
[2]
|
Molodecky, N.A., Soon, I.S., Rabi, D.M., et al. (2011) Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology, 142, 46-54.
|
[3]
|
Loftus Jr., E.V. (2004) Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology, 126, 1504-1517.
doi:10.1053/j.gastro.2004.01.063
|
[4]
|
Ahuja, V. and Tandon, R.K. (2010) Inflammatory bowel disease in the Asia-Pacific area: A comparison with developed countries and regional differences. Journal of Digestive Diseases, 11, 134-147.
doi:10.1111/j.1751-2980.2010.00429.x
|
[5]
|
Yao, T., Matsui, T. and Hiwatashi, N. (2000) Crohn’s disease in Japan: Diagnostic criteria and epidemiology. Diseases of the Colon & Rectum, 43, S85-S93.
doi:10.1007/BF02237231
|
[6]
|
Yamamoto, S., Nakase, H., Mikami, S., et al. (2008) Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. Alimentary Pharmacology & Therapeutics, 28, 589-597.
doi:10.1111/j.1365-2036.2008.03764.x
|
[7]
|
Colombel, J.F., Sandborn, W.J., Rutgeerts, P., et al. (2007) Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: The CHARM trial. Gastroenterology, 132, 52-65.
doi:10.1053/j.gastro.2006.11.041
|
[8]
|
Ogata, H., Matsui, T., Nakamura, M., et al. (2006) A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut, 55, 1255 1262. doi:10.1136/gut.2005.081794
|
[9]
|
Shibolet, O., Regushevskaya, E., Brezis, M. and Soares Weiser K. (2005) Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database of Systematic Reviews, 25, Article ID: CD004277.
|
[10]
|
Rutgeerts, P., Sandborn, W.J., Feagan, B.G., et al. (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine, 353, 2462-2476. doi:10.1056/NEJMoa050516
|
[11]
|
Rutgeerts, P., Van Assche, G. and Vermeire, S. (2004) Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology, 126, 1593-1610.
doi:10.1053/j.gastro.2004.02.070
|
[12]
|
Kornbluth, A. and Sachar, D.B. (2010) Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. American Journal of Gastroenterology, 105, 501-523.
doi:10.1038/ajg.2009.727
|
[13]
|
Lichtenstein, G.R., Hanauer, S.B. and Sandborn, W.J. (2009) Management of Crohn’s disease in adults. American Journal of Gastroenterology, 104, 465-483.
|
[14]
|
Mowat, C., Cole, A., Windsor, A., et al. (2011) Guidelines for the management of inflammatory bowel disease in adults. Gut, 60, 571-607. doi:10.1136/gut.2010.224154
|
[15]
|
Matsui, T. and Ueno, F. (2010) Crohn’s disease practice guidelines in Japan. Nihon Shokakibyo Gakkai Zasshi, 107, 1887-1896.
|
[16]
|
Hibi, T., Ueno, F., Matsuoka, K. and Lee, T. (2010) Guidelines for the management of ulcerative colitis in Japan. IBD Research, 4, 189-239.
|
[17]
|
Reddy, S.I., Friedman, S., Telford, J.J., Strate, L., Ookubo, R. and Banks, P.A. (2005) Are patients with inflammatory bowel disease receiving optimal care? Ame rican Journal of Gastroenterology, 100, 1357-1361.
doi:10.1111/j.1572-0241.2005.40849.x
|
[18]
|
Stange, E.F., Travis, S.P., Vermeire, S., et al. (2006) European evidence based consensus on the diagnosis and management of Crohn’s disease: Definitions and diagnosis. Gut, 55, i1-i15. doi:10.1136/gut.2005.081950a
|
[19]
|
Bergman, R. and Parkes, M. (2006) Systematic review: The use of mesalazine in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics, 23, 841-855.
doi:10.1111/j.1365-2036.2006.02846.x
|
[20]
|
Sutherland, L. and Macdonald, J.K. (2006) Oral 5-amino salicylic acid for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews, 3, Article ID: CD000543.
|
[21]
|
Yamamoto, T., Umegae, S. and Matsumoto, K. (2011) High-dose mesalazine treatment for ulcerative colitis patients who relapse under low-dose maintenance therapy. Digestive and Liver Disease, 43, 386-390.
doi:10.1016/j.dld.2010.11.016
|
[22]
|
Hiwatashi, N., Suzuki, Y., Mitsuyama, K., Munakata, A. and Hibi, T. (2011) Clinical trial: Effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study. Journal of Gastroenterology, 46, 46-56.
doi:10.1007/s00535-010-0308-3
|
[23]
|
Hanauer, S.B., Sandborn, W.J., Kornbluth, A., et al. (2005) Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: The ASCEND II trial. American Journal of Gastroenterology, 100, 2478-2485.
doi:10.1111/j.1572-0241.2005.00248.x
|
[24]
|
Ransford, R.A. and Langman, M.J. (2002) Sulphasalazine and mesalazine: Serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut, 51, 536-539.
doi:10.1136/gut.51.4.536
|
[25]
|
Loftus Jr., E.V., Kane, S.V. and Bjorkman, D. (2004) Systematic review: Short-term adverse effects of 5-ami nosalicylic acid agents in the treatment of ulcerative colitis. Alimentary Pharmacology & Therapeutics, 19, 179 189. doi:10.1111/j.0269-2813.2004.01827.x
|
[26]
|
Sutherland, L. and Macdonald, J.K. (2006) Oral 5-amino salicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews, 4, CD000544.
|
[27]
|
Marteau, P., Probert, C.S., Lindgren, S., et al. (2005) Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: A randomised, double blind, placebo controlled study. Gut, 54, 960-965. doi:10.1136/gut.2004.060103
|
[28]
|
Faubion Jr., W.A., Loftus Jr., E.V., Harmsen, W.S., Zinsmeister, A.R. and Sandborn, W.J. (2001) The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study. Gastroenterology, 121, 255-260. doi:10.1053/gast.2001.26279
|
[29]
|
Strassburg, C.P. and Manns, M.P. (2011) Therapy of autoimmune hepatitis. Best Practice & Research Clinical Gastroenterology, 25, 673-687.
doi:10.1016/j.bpg.2011.08.003
|
[30]
|
George, J.N. (2006) Management of patients with refractory immune thrombocytopenic purpura. Journal of Thro mbosis and Haemostasis, 4, 1664-1672.
doi:10.1111/j.1538-7836.2006.02013.x
|
[31]
|
Dignass, A., Van Assche, G., Lindsay, J.O., et al. (2010) The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Current management. Journal of Crohn’s and Colitis, 4, 28-62.
doi:10.1016/j.crohns.2010.07.001
|
[32]
|
Hibi, T., Naganuma, M., Kitahora, T., Kinjyo, F. and Shimoyama, T. (2003) Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis. Journal of Gastroenterology, 38, 740 746. doi:10.1007/s00535-003-1139-2
|
[33]
|
Hibi, T., Iwao, Y., Yajima, T., et al. (1995) Immunosuppressive agents in the treatment of Crohn’s disease and ulcerative colitis. Journal of Gastroenterology, 30, 121 123.
|
[34]
|
Dubinsky, M.C., Yang, H., Hassard, P.V., et al. (2002) 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology, 122, 904-915.
doi:10.1053/gast.2002.32420
|
[35]
|
Takatsu, N., Matsui, T., Murakami, Y., et al. (2009) Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease. Journal of Gastroenterology and Hepatology, 24, 1258-1264.
doi:10.1111/j.1440-1746.2009.05917.x
|
[36]
|
Hindorf, U., Johansson, M., Eriksson, A., Kvifors, E. and Almer, S.H. (2009) Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease. Alimentary Pharmacology & Therapeutics, 29, 654-661.
doi:10.1111/j.1365-2036.2008.03925.x
|
[37]
|
Kuriyama, M., Kato, J., Suzuki, H., et al. (2010) Tolerability and usefulness of mercaptopurine in azathioprine-intolerant Japanese patients with ulcerative colitis. Digestive Endoscopy, 22, 289-296.
doi:10.1111/j.1443-1661.2010.01009.x
|
[38]
|
Domenech, E., Nos, P., Papo, M., Lopez-San Roman, A., Garcia-Planella, E. and Gassull, M.A. (2005) 6-mercaptopurine in patients with inflammatory bowel disease and previous digestive intolerance of azathioprine. Scandinavian Journal of Gastroenterology, 40, 52-55.
|